Startseite: Forschungsbericht      Personenindex      Schlagwortindex      zugeh.Orgeinheit            Page in english      Impressum+Datenschutz   


Development of Novel Management strategies for invasive aspergillosis, MANASP

Projektleitung an der Universität Würzburg:

Beteiligte Wissenschaftlerinnen und Wissenschaftler:


·         Our proposal is to develop new treatment strategies for Invasive Aspergillosis (IA) which has become the major infectious complication of treating haematological malignancies with intensive chemotherapy or haematopoietic stem cell transplantation (HSCT).

·         It meets the criteria of the call by addressing a disease with a significant economic cost due to resistance to treatment with available agents and high associated mortality.

·         Ineffective host immune responses facilitate fungal invasion of the pulmonary system and other vital organs leading to death. In order to redress this immunological imbalance we propose to develop new immunotherapeutic strategies which will augment current antifungal treatments and reduce morbidity and mortality.

·         We plan to study high risk patients undergoing alllogeneic HSCT to prove our hypothesis that immunotherapy is efficacious.

·         Facilitated by recent publication of the Aspergillus fumigatus (the principal pathogen of the genus) genome sequence we will exploit new knowledge and techniques in genomics and proteomics. We will identify the immunologically important fungal targets to aid design of immunotherapies based on vaccines using fungus-primed innate immune cells, monoclonal antibodies or adoptive transfer of specificT lymphocyte clones.

·         We will also generate new nucleic acid based diagnostic tests to inform when and how immunotherapy can be optimally applied.

·         The findings generated will be of great relevance to treatment of haematological malignancies throughout the EU by significantly reducing HSCT related mortality, by allowing more intensive cancer treatment regimens to be used leading to higher remission rates, and will also be applicable  to other patient populations at risk of IA.

·         The outcomes will have strong commercial applications which will be delivered by three leading European SMEs within the consortium.

Laufzeit: von 11.2006 bis 12.2009

EU ( FP 6 - MANASP ) ,Genehmigungsdatum: 30.11.06